Atherosclerotic cardiovascular disease is the main cause of morbidity and mortality in chronic kidney disease patients. There is a raft of evidence showing that in the general population dyslipidaemia is associated with an increased risk of cardiovascular events, as well as with a greater prevalence of chronic kidney disease. Consequently, the use of statins in the general population with dysli...

BACKGROUND The prevalence of cardiovascular disease is projected to be 38.7% for the USA in 2020, including coronary heart disease at 8.6% and stroke at 3.6%. In South Africa (SA), premature deaths due to heart and blood vessel diseases in people of working age (35 - 64 years) have been predicted to increase by 41% between 2007 and 2030, with enormous negative economic impact. Atherosclerosis u...

Dyslipidaemia is an important risk factor in the development of atherosclerotic cardiovascular disease people with diabetes. This article discusses lipid modifying therapies available, and current evidence guidance on their use

objective vitamin e is a major lipid-soluble antioxidant. it has been demonstrated that vitamin e supplementation has a beneficial effect against coronary heart disease (chd). this study to investigate the effects of coronary risk factors on serum vitamin e status in patients with dyslipidaemia. materials and methods this tertiary care hospital; case - control study was comprised 237 dyslipidae...